Epstein–Barr virus-infected subcutaneous panniculitis-like T-cell lymphoma associated with methotrexate treatment
- 28 July 2010
- journal article
- case report
- Published by Springer Nature in International Journal of Hematology
- Vol. 92 (2) , 364-368
Abstract
Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is a lymphoid proliferation or lymphoma in patients treated with MTX. We report a case of Epstein–Barr virus (EBV)-positive subcutaneous panniculitis-like T-cell lymphoma (SPTCL) in a 60-year-old Japanese man treated with MTX for rheumatoid arthritis (RA). SPTCL is a rare cytotoxic T-cell lymphoma characterized by involvement of subcutaneous fat mimicking panniculitis. The patient, who had been on MTX therapy for RA, manifested high fever and lumbago. Physical examination showed multiple subcutaneous nodules on the trunk including axillary and inguinal regions. Biopsy of the inguinal nodule showed profuse infiltration of CD8+ T-cell lymphoma cells in the subcutaneous adipose tissues. A diagnosis of SPTCL was made according to the diagnostic criteria of World Health Organization classification. EBV-encoded small RNA in situ hybridization revealed that the lymphoma cells contained EBV genome. The cells were positive for EBV latent membrane protein 1, but not for EBNA2. After discontinuation of MTX, the nodules regressed spontaneously. Studies have reported that most MTX-LPDs are B-cell type lymphomas and Hodgkin lymphoma. To the best of our knowledge, EBV-positive SPTCL has not been reported in patients receiving MTX. Our case emphasizes the importance of clinical and virological characterization of MTX-associated SPTCL.Keywords
This publication has 21 references indexed in Scilit:
- Age‐related EBV‐associated B‐cell lymphoproliferative disorders: Diagnostic approach to a newly recognized clinicopathological entityPathology International, 2009
- Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritisBritish Journal of Dermatology, 2009
- Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomasAnnals of the Rheumatic Diseases, 2005
- Reactivation of Latent Epstein-Barr Virus by Methotrexate: A Potential Contributor to Methotrexate-Associated LymphomasJNCI: Journal of the National Cancer Institute, 2004
- Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphomaBlood, 2003
- Spontaneous remission of low‐grade B‐cell non‐Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literatureBritish Journal of Haematology, 2002
- Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in FranceBlood, 2002
- Subcutaneous Panniculitis-like T-Cell LymphomaAmerican Journal of Surgical Pathology, 1998
- Methotrexate‐associated lymphoma in patients with rheumatoid arthritis. Report of two casesArthritis & Rheumatism, 1996
- Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pyloriThe Lancet, 1993